What is Valted Seq?
Founded in 2019 and headquartered in Gaithersburg, Maryland, Valted Seq is a biotechnology firm dedicated to the genetic elucidation of neurodegenerative disease pathways. The company's core focus is on accelerating the development of novel therapeutics and diagnostics to combat these debilitating conditions. Valted Seq operates within the dynamic biotech sector, aiming to leverage genetic insights for groundbreaking medical advancements.
How much funding has Valted Seq raised?
Valted Seq has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2021): $10M with participation from OV Principal Investments and DongKoo Bio&Pharma
Key Investors in Valted Seq
OV Principal Investments
OV Principal Investments is an entity involved in the funding round. Further details on their investment focus are not publicly available.
DongKoo Bio&Pharma
DongKoo Bio & Pharma is a leading pharmaceutical company in South Korea, recognized for its innovative approach to healthcare. The company specializes in a range of products including prescription medications, over-the-counter drugs, cosmetics, and medical devices, with a strong focus on research and development.
What's next for Valted Seq?
The recent major enterprise-level funding positions Valted Seq for significant expansion and accelerated research and development. This capital infusion is expected to fuel the company's efforts in refining its therapeutic candidates and diagnostic tools, potentially leading to breakthroughs in treating neurodegenerative diseases. The strategic backing suggests confidence from investors in Valted Seq's scientific approach and market potential, paving the way for future growth and clinical milestones.
See full Valted Seq company page
